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i.org/1(LVAD) implantation and heart transplantation (HT) on physical activity and quality of life
(QoL). Forty patients (LVAD, n[ 14; HT, n[ 12; and heart failure [HF], n[ 14) and 14
matched healthy subjects were assessed for physical activity, energy expenditure, and QoL.
The LVAD and HT groups were assessed postoperatively at 4 to 6 weeks (baseline) and 3, 6,
and 12 months. At baseline, LVAD, HT, and HF patients demonstrated low physical ac-
tivity, reaching only 15%, 28%, and 51% of that of healthy subjects (1,603 – 302 vs 3,036 –
439 vs 5,490 – 1,058 vs 10,756 – 568 steps/day, respectively, p <0.01). This was associated
with reduced energy expenditure and increased sedentary time (p <0.01). Baseline QoL was
not different among LVAD, HT, and HF groups (p [ 0.44). LVAD implantation and HT
signiﬁcantly increased daily physical activity by 60% and 52%, respectively, from baseline to
3 months (p <0.05), but the level of activity remained unchanged at 3, 6, and 12 months. The
QoL improved from baseline to 3 months in LVAD implantation and HT groups (p <0.01)
but remained unchanged afterward. At any time point, HT demonstrated higher activity
level than LVAD implantation (p <0.05), and this was associated with better QoL. In
contrast, physical activity and QoL decreased at 12 months in patients with HF (p <0.05). In
conclusion, patients in LVAD and HT patients demonstrate improved physical activity and
QoL within the ﬁrst 3 months after surgery, but physical activity and QoL remain unchanged
afterward and well below that of healthy subjects. Strategies targeting low levels of physical
activity should now be explored to improve recovery of these patients.  2014 The Au-
thors. Published by Elsevier Inc. All rights reserved. (Am J Cardiol 2014;114:88e93)Physical inactivity increases the risk for all-cause and
cardiovascular mortality by 30% to 40% in the general pop-
ulation1 and is considered as an independent risk factor for
heart failure (HF).2 Conversely, habitual physical activity,
that is, daily walking performance, as objectively evaluated
by an accelerometer, is an important determinant of functional
capacity in patients with chronic HF.3 Furthermore, increased
physical activity in the form of a structured exercise inter-
vention improves exercise tolerance and quality of life (QoL)llularMedicine, Faculty ofMedical Sciences, and fInstitute
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0.1016/j.amjcard.2014.04.008in HF4 and heart transplantation (HT) patients,5 but limited
number of studies evaluated its impact in patients implanted
with a left ventricular assist device (LVAD).6,7 Before criti-
cally evaluating exercise as a potential therapy for patients on
LVAD support, it is important to understand the pattern of
habitual, daily physical activity and its relation to QoL.
Consequently, the aim of this study was to deﬁne the short-
and long-term effects of LVAD implantation and HT on
everyday physical activity, energy expenditure, and QoL.
Methods
A prospective, observational, repeated-measures design
was chosen to characterize changes over time that occur in
physical activity and QoL in patients on LVAD support and
HT patients. The setting for the study was an inpatient HT
assessment. Based on the assessment, patients were listed for
HT, if judged to be too unwell to wait for a transplant, or an
LVADwas implanted, if they would become better transplant
candidates after a period of LVAD support. Those toowell for
transplant were continued on optimal medical management.
These 3 scenarios were the basis of the 3 patients groups:
LVAD, HT, and HF. HF patients had not received LVAD
or HT during the study. Changes in physical activity and QoL
of 12 HT patients were compared with those of 14 LVAD and
14 HF patients. Physical activityerelated subgroup compar-
isons were performed with age-, gender-, and body masswww.ajconline.org
Table 1
Subject demographic and clinical characteristics
Patients Characteristics LVAD
(n ¼ 14)
HT
(n ¼ 12)
HF
(n ¼ 14)
Healthy
Subjects (n ¼ 14)
ANOVA
p Value
Age (years) 49  14 48  17 46  10 48  14 0.959
Men (%) 100 70 67 71 —
Weight (kg) 85  16 77  11 80  15 84  17 0.617
Height (cm) 177  10 170  8 169  9 174  13 0.081
Body mass index (kg/m2) 27  6 27  6 29  5 27  4 0.725
Etiology of heart failure
Idiopathic dilated cardiomyopathy 5 6 11 N/A —
Ischemic cardiomyopathy 9 2 3 N/A —
Other — 4 — N/A —
LVEF (%) 13  2 14  6 18  3 64  8 0.004*
NYHA class 3.7  0.2 3.8  0.3 3.3  0.5 —
Cardiac index (l/min/m2) 1.7  0.4 1.8  0.3 4 2.1  0.4 3.6  0.7 0.002*
Peak O2 consumption (ml/kg/min) 9.9  2.1 10.2  2.3 14.6  2.8 34.6  9.2
INTERMACS score 2.8  0.9 — — — —
Other includes tricuspid atresia (2) and restrictive cardiomyopathy (2).
ANOVA ¼ analysis of variance; HF ¼ heart failure; HT ¼ heart transplantation; LVAD ¼ left ventricular assist device; LVEF ¼ left ventricular ejection
fraction; NYHA ¼ New York Heart Association functional class.
* Healthy versus LVAD, HT, and chronic heart failure (p <0.01).
Table 2
Energy expenditure, physical activity and quality of life at baseline
Variables LVAD HT HF Healthy
Subjects
ANOVA
p Value
Total energy expenditure (kcal/day) 2164  112 2240  163 2108  211 2880  153 0.004*
Steps (per day) 1603  302 3036  439 5490  1058 10,756  568 <0.001*†
Average METs (kcal/kg/hour) 1.07  0.06 1.28  0.08 1.23  0.06 1.45  0.04 <0.001*z
Active energy expenditure (kcal/day) 78  30 330  129 313  95 751  77 <0.001*z
Physical activity duration (min/day) 18  8 69  22 65  18 128  10 <0.001*z
Sedentary time (min/day) 1410  10 1303  32 1322  24 1261  17 <0.001z
Moderate physical activity (min/day) 18  8 66  25 64  18 120  9 <0.001*z
Vigorous physical activity (min/day) 0  0 3.5  2.3 0.5  0.3 5.9  1.7 0.014x
Very vigorous physical activity (min/day) 0  0 0.1  0.3 0  0 1.6  1.5 0.489
MLHF quality of life 81  5 72  8 74  4 N/A 0.445
ANOVA ¼ analysis of variance; HF ¼ heart failure; HT ¼ heart transplantation; LVAD ¼ left ventricular assist device; METs ¼ metabolic equivalent units;
MLHF ¼ Minnesota Living with Heart Failure Questionnaire; N/A ¼ not applicable.
* Healthy versus LVAD, HT, and HF (p <0.05).
† LVAD versus HF (p <0.05).
z LVAD versus HF, HT, and healthy (p <0.05).
x Healthy and HT versus HF and LVAD (p <0.05).
Heart Failure/Effects of LVAD Implantation and HT 89indexematched 14 HF patients and 14 healthy subjects. In
LVAD and HT patients, data on physical activity and QoL
were collected at 4 different time points: baseline assessment,
that is, 4 to 6 weeks after surgery and after discharge from
hospital and then follow-up assessments at 3, 6, and
12 months after surgery. The data on patients with HF were
collected at baseline and at 12 months, and on the healthy
subjects data were only collected at 1 time point. Both LVAD
and HT patients completed in-hospital postsurgery mobility
and rehabilitation program guided by a physiotherapist. The
study protocol was approved by the County Durham and Tees
Valley Research and Ethics Committee. All participants gave
written informed consent. All clinical investigations were
conducted according to the principles expressed in the
Declaration of Helsinki.
All patients undergoing LVAD implantation (HeartWare,
HeartWare International Inc., Framingham, Massachusetts)or HTwhomet study inclusion criteria were recruited into the
study from September 2010 to June 2013 at the Freeman
Hospital, Newcastle upon Tyne, United Kingdom. Their
baseline physical activity and QoL data were compared with
those of 14 patientswith chronic HFwhowere assessed but not
listed for HT and 14 healthy participants. Subjects’ de-
mographic and clinical characteristics are presented in Table 1.
The study inclusion criteria included age from 18 to 60 years,
sufﬁcient English language skills to answer the questionnaires,
completion of follow-up visits, and willingness to participate.
Study exclusion criteria included physical condition limiting
rehabilitation or mobility such as stroke; myopathy; neuropa-
thy; renal, pulmonary, or hepatic dysfunction; or active un-
controlled infection. Written informed consent was received
from all subjects enrolled in the study.
Patients on LVAD support were treated with warfarin for a
target international normalized ratio of 2.7 and antiplatelets
Table 3
Longitudinal changes in energy expenditure, physical activity, and quality of life
Variables Patient Group Baseline 3 Months 6 Months 12 Months
Weight (kg) LVAD 86  17 86  16 89  16 83  11
HT 76  15 78  14 77  15 80  17
HF 81  17 — — 82  16
Steps (per day) LVAD 1603  302 3712  807 4007  1084 3997  956*
HT 3036  439 6265  443 6563  824 6288  701*
HF 5490  1058 — — 3560  885*†
Total energy expenditure (kcal/day) LVAD 2164  112 2392  105 2398  108 2421  117*
HT 2240  163 2406  137 2443  148 3572  202*z
HF 2108  211 — — 1989  198†
Average METs (kcal/kg/hour) LVAD 1.07  0.06 1.18  0.07 1.19  0.08 1.20  0.09
HT 1.28  0.08z 1.31  0.05 1.35  0.07z 1.39  0.06z
HF 1.23  0.06 — — 1.14  0.05†
Sedentary time (min/day) LVAD 1410  10 1353  26 1293  52 1280  62
HT 1303  32 1308  21 1329  18 1260  29
HF 1322  24 — — 1388  21†
Moderate physical activity (min/day) LVAD 18  8 48  17 55  16 51  20*
HT 66  22z 86  46z 84  14z 144  22xz
HF 64  18 — — 41  12*†
Vigorous physical activity (min/day) LVAD 0  0 1.3  0.7 2.4  1.9 0.5  0.3
HT 3.5  2.3 2.3  1.3 2.9  1.5 4.3  2.3
HF 0.5  0.3 — — 0  0
Very vigorous physical activity (min/day) LVAD 0  0 0  0 0  0 0  0
HT 0  0 0  0 0  0 0  0
HF 0  0 — — 0  0
MLHF quality of life LVAD 81  5 57  7 63  7 60  5*
HT 72  8 39  5z 30  6z 29  7*z
HF 74  4 — — 82  6*†k
* p <0.05, 12 months versus baseline.
† p <0.05, HF versus HT.
z p <0.05, HT versus LVAD.
x p <0.05, 12 months versus 3 and 6 months.
k p <0.05, HF versus LVAD.
90 The American Journal of Cardiology (www.ajconline.org)as well as with angiotensin-converting enzyme inhibitors,
b blockers, aldosterone antagonists, angiotensin receptor
blockers, and diuretics as appropriate. HT patients received
triple-drug immunosuppressive maintenance therapy, usually
including a calcineurin inhibitor, prednisolone, and azathio-
prine. Patients with chronic HF were treated with b blockers
(n¼ 14), angiotensin-converting enzyme inhibitors (n¼ 10),
aldosterone antagonists (n ¼ 6), diuretics (n ¼ 12), statins
(n¼ 8), angiotensin receptor blockers (n¼ 5), anticoagulants
(n ¼ 9), antiarrhythmics (n ¼ 5), and digoxin (n ¼ 3).
Habitual physical activity was objectively evaluated using
a validated portable multisensor array (SenseWear Pro3,
BodyMedia Inc., Pennsylvania).8 Themonitor wasworn for 7
days andwas only removed for bathing. Themultisensor array
measures 4 key metrics: skin temperature, galvanic skin
response, heat ﬂux, and motion by way of a 3-axis acceler-
ometer. The sensors, combined with algorithms, calculate the
average daily energy expenditure relative to baseline meta-
bolism (metabolic equivalent:MET per day [1MET¼ resting
metabolic rate]), total energy expenditure (calories per day),
active energy expenditure (total calories expended over 3
METs per day), physical activity duration (minutes>3METs
per day), average daily number of steps walked, sedentary
activity (minutes <3 METs per day), moderate activity
(minutes between 3 and 6 METs per day), vigorous activity
(minutes between 6 and 9 METs day), and very vigorousactivity (minutes >6 METs day).8,9 HF-related QoL was
assessed with the Minnesota Living with Heart Failure
(MLHF) Questionnaire.10
All statistical analyses were carried out using SPSS,
version 19.0 (SPSS Inc., Chicago, Illinois). Before statistical
analysis, data were checked for univariate and multivariate
outliers using standard z-distribution cutoffs and Mahala-
nobis distance tests. Normality of distribution was assessed
using a Kolmogorov-Smirnov test. Analysis of variance was
used to test differences in physical activity and QoL among
LVAD, HT, and HF patients and healthy controls as well as
to evaluate changes at different time points in LVAD and
HT patients. To identify groups that differed signiﬁcantly
from one another, a post hoc Tukey test was performed. The
relation between QoL and physical activity in the patients
was evaluated using the Pearson coefﬁcient of correlation.
Statistical signiﬁcance was indicated if p <0.05. All data are
presented as mean  SEM unless otherwise indicated.
Results
The total number of patients screened for the study was
52 (18 LVAD, 14 HT, and 20 HF). Study participants’
demographic and clinical characteristics are described in
Table 1. The groups were not randomly assigned, and the
treatment was based on the outcome of the transplant
Figure 1. Longitudinal changes in the daily number of steps (A), physical activity duration (B), active energy expenditure (C), and QoL (D). Healthy data is a
single reference data point and not a longitudinal series of data. *p <0.05, HT versus LVAD; †p <0.05, HF versus LVAD; zp <0.05, HF versus HT.
Heart Failure/Effects of LVAD Implantation and HT 91assessment. No signiﬁcant differences were found in age and
body mass index among LVAD, HT, HF, and healthy sub-
jects. During the follow-up study, 2 patients in the LVAD
group died and 2 refused to complete the study. There were 8
hospitalizations in 7 patients in the LVAD group for in-
fections, 2 hospitalizations for arrhythmias, 1 with HF, 1
anemia, 1 with a transient ischemic attack, 1 with a possible
deep vein thrombosis, and 1 with light-headedness. Of the
heart transplant patients, 3 patients had admissions for in-
fections and 1 patient had 3 admissions for rejection. Of the 20
patients with HFwhowere initially screened, 4 refused to take
part in the study, 2 received HT, and 10 of remaining 14 pa-
tients completed investigation at 12 months after the baseline
assessment.
Baseline physical activity measures demonstrated that
patients in the LVAD and HT groups expended 25%
(716 kcal) and 22% (640 kcal) less energy per day, respec-
tively, in comparison with healthy subjects (p <0.05). Simi-
larly, patients with HF expended 27% (772 kcal) less energy
per day than healthy subjects (Table 2). Daily physical ac-
tivity (i.e., number of steps) was signiﬁcantly reduced in the 3
patient groups with LVAD and HT patients at baseline per-
forming only 15% and 28% and HF 51% of that of healthy
subjects (Table 2). At baseline, duration of physical activity
(i.e., >3 METs) was signiﬁcantly reduced in LVAD patients
comparedwith bothHT andHF patients (Table 2). LVADand
HT patients showed active energy expenditure that was
signiﬁcantly lower than that of healthy subjects (Table 2).
Moderate physical activity, that is, 3 to 6 METs, was a majorcontributor to active energy expenditure in all 4 groups.
Vigorous physical activity was identiﬁed in healthy and HT
participants but not in LVAD and HF patients (Table 2). The
MLHF QoL score was not signiﬁcantly different among the
3 groups of patients at baseline (Table 2).
During the follow-up period there were no signiﬁcant
changes in body mass during 12 months after LVAD implan-
tation or HT. The body mass was also not changed in patients
withHF.Total daily energy expenditure increased signiﬁcantly
from baseline to 3 months in LVAD patients (p <0.05) but
remained unchanged from 3 to 12 months after the surgery. In
contrast, HT patients demonstrated signiﬁcantly higher total
energy expenditure at 12 months (Table 3). Daily number of
steps signiﬁcantly increased by 60% and 52% from baseline to
3 months in LVAD and HT patients, respectively. It remained,
however, unchanged from 3 to 12 months and signiﬁcantly
lower than that of healthy subjects (Figure 1). This was further
associated with signiﬁcant increase in physical activity dura-
tion and active energy expenditure (Figure 1). MLHF scores
decreased over time from baseline in both LVAD and HT pa-
tients indicating an improvement inQoL (Table 3, Figure 1). In
contrast with LVAD and HT patients, those with HF had
decreased daily number of steps, activity duration, and active
energy expenditure at 12 months from baseline and increased
MLHF scores (Figure 1).
At any time point during the 12-month follow-up, LVAD
patients demonstrated signiﬁcantly lower number of steps,
physical activity duration, and active energy expenditure in
comparison with HT patients (Figure 1). HT patients at
92 The American Journal of Cardiology (www.ajconline.org)12 months after surgery demonstrated average daily phys-
ical activity duration that was only 7% below healthy con-
trols (119 vs 128 min/day) and reached 80% active energy
of controls (602 vs 751 kcal/day). The QoL score was
signiﬁcantly lower in HT than in LVAD patients at 3, 6, and
12 months after surgery (Figure 1).
Discussion
To our knowledge, this is the ﬁrst study to report physical
activity in patients after LVAD implantation and HT. There
are 3 major ﬁndings. First, within the ﬁrst 4 to 6 weeks after
surgery, LVAD and HT patients demonstrated low physical
activity levels accompanied with low energy expenditure
and increased sedentary time. Second, from baseline to
3 months there was a signiﬁcant increase in physical acti-
vityeassociated measures and improvement in QoL in both
LVAD and HT, but the number of steps remained un-
changed from 3 to 12 months after surgery. Finally, HT
patients demonstrate higher activity level and better QoL
than LVAD patients during the 12-month follow-up. In
contrast with HT and LVAD patients, those with HF
demonstrated a decrease in physical activityeassociated
measures at 12 months compared with baseline.
The HT and particularly LVAD patients showed low ac-
tivity levels on hospital discharge. Although both LVAD and
HT patients completed in-hospital postsurgery mobility and
rehabilitation program, they remained inactive. Strong asso-
ciation between daily walking performance and functional
capacity in HF has been reported.3 It is therefore not sur-
prising that LVAD and HT patients a few weeks after surgery
demonstrate only w40% and w50% of maximal predicted
functional capacity, respectively.11,12 Inactivity, low energy
expenditure, and diminished functional performance early
after the surgery are likely to be due to a high incidence of
psychological distress and deconditioning found in LVAD
and HT patients early after the surgery.11,13
In comparison with baseline, there was a signiﬁcant
improvement in physical activityeassociated measures and
QoL at 3 months after surgery in both LVAD and HT pa-
tients. That QoL and functional capacity improve on hos-
pital discharge during longitudinal follow-up of LVAD and
HT patients has been previously reported.12,14,15 It is,
however, noticeable that increased daily activity level at
3 months in LVAD and HT patients, found in the present
study, is markedly below healthy controls and in case of HT
patients similar to that of HF patients. It should further be
noted that QoL improved from baseline to 3 months by 24
and 33 points for LVAD and HT patients, respectively. This
is important, as a 5-point change in the MLHF score has
been previously determined to be clinically meaningful.10
Further comparison between the different patient groups
reveals that 3 months after surgery, LVAD and HT patients
show better QoL than patients with HF. QoL was not
changed from 3 to 12 months in LVAD patients, likely
because of frequent hospitalization. Our ﬁndings further
suggest that patients’ body mass remained unchanged over
time. This is particularly interesting for LVAD patients and
contrasts ﬁndings from a recent large retrospective study
that suggests a signiﬁcant increase in body mass after a
continuous LVAD implantation.16 The limited number ofpatients recruited in the present study may limit general-
ization of our ﬁndings.
Our data further suggest that daily number of steps and
QoL remained unchanged at 3, 6, and 12months after surgery
for LVAD, but the QoL was further improved at 6 months in
HT patients. This is surprising, as a signiﬁcant improvement
in functional capacity has been reported several months after
HT and LVAD implantation allowing patients to indepen-
dently perform activities of daily living.12,17,18 In agreement
with our ﬁndings, previous studies also showed that health-
related QoL improved from baseline to 3 months after sur-
gery and remained unchanged during 1-year follow-up.14,19
Finally, our results suggest that, not only at baseline but also
at 3, 6, and 12 months after surgery, HT patients demonstrate
higher levels of physical activity and better QoL than LVAD
patients. These ﬁndings are in line with previous studies sug-
gesting greater functional capacity of HT compared with
LVAD patients.7,11,12,20 In contrast with LVAD patients who
showed a plateauing during the follow-up, HT patients at
12 months demonstrated physical activity duration and active
energy expenditure thatwere 93%and80%ofhealthy controls,
respectively. This is an interesting ﬁnding considering that the
number of steps remained unchanged from 3 to 12 months. A
plausible explanation for suchﬁnding is that from3 to6months
the intensity of the activity was mostly <3 METs (character-
ized as sedentary activity), whereas at 12 months moderate
activity (3 to 6METs)was predominantly detected, resulting in
a signiﬁcant increase in activity duration and active energy
expenditure. It has further been suggested that vigorous in-
tensity appears to convey greater cardiovascular and functional
beneﬁts than exercise of a moderate intensity.21 Considering
that HT and LVAD are different treatment methods, the
optimal physical activity and exercise interventions to improve
outcomes in these patients remain to be determined in large
clinical trials. Therefore, general recommendations for exercise
therapy in HT and LVAD patients need to be considered with
caution and are likely to differentiate in volume and intensity
from those of general cardiology patients.
The present study is not without limitations. First, the
lack of presurgical activity monitoring prevents our under-
standing of individual variation in daily activity level be-
tween HT and LVAD implantation candidates. Second,
small sample size limits the generalizability of our ﬁndings.
Finally, the study may be biased by the fact that predomi-
nantly male patients were available for this analysis,
particularly in LVAD group.Acknowledgment: The authors thank the participants for
contributing to this study. In addition, we acknowledge the
signiﬁcant contribution from Judith Coulson, BSc, the
research nurse, for helping with study recruitment, data
collection, and follow-up of patients.
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